ID   UKF-NB-2rVCR10
AC   CVCL_9910
SY   UKF-NB-2 VCR
DR   Wikidata; Q54990306
RX   PubMed=12532417;
RX   PubMed=16151587;
RX   PubMed=17505515;
RX   PubMed=22170099;
RX   PubMed=25749379;
WW   https://www.wass-michaelislab.org/rccl.php
CC   Part of: Resistant Cancer Cell Line (RCCL) collection.
CC   Doubling time: 27 hours (PubMed=12532417).
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_9902 ! UKF-NB-2
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 29-06-23; Version: 15
//
RX   PubMed=12532417; DOI=10.1002/ijc.10917;
RA   Kotchetkov R., Cinatl J., Blaheta R.A., Vogel J.-U., Karaskova J.,
RA   Squire J.A., Hernaiz Driever P., Klingebiel T., Cinatl J. Jr.;
RT   "Development of resistance to vincristine and doxorubicin in
RT   neuroblastoma alters malignant properties and induces additional
RT   karyotype changes: a preclinical model.";
RL   Int. J. Cancer 104:36-43(2003).
//
RX   PubMed=16151587;
RA   Bedrnicek J., Vicha A., Jarosova M., Holzerova M., Cinatl J. Jr.,
RA   Michaelis M., Cinatl J., Eckschlager T.;
RT   "Characterization of drug-resistant neuroblastoma cell lines by
RT   comparative genomic hybridization.";
RL   Neoplasma 52:415-419(2005).
//
RX   PubMed=17505515; DOI=10.1038/sj.bjc.6603777;
RA   Blaheta R.A., Michaelis M., Natsheh I., Hasenberg C., Weich E.,
RA   Relja B., Jonas D., Doerr H.-W., Cinatl J. Jr.;
RT   "Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant
RT   neuroblastoma tumour cells to endothelium.";
RL   Br. J. Cancer 96:1699-1706(2007).
//
RX   PubMed=22170099; DOI=10.1038/cddis.2011.129;
RA   Michaelis M., Rothweiler F., Barth S., Cinatl J., van Rikxoort M.,
RA   Loschmann N., Voges Y., Breitling R., von Deimling A., Rodel F.,
RA   Weber K., Fehse B., Mack E., Stiewe T., Doerr H.-W., Speidel D.,
RA   Cinatl J. Jr.;
RT   "Adaptation of cancer cells from different entities to the MDM2
RT   inhibitor nutlin-3 results in the emergence of p53-mutated
RT   multi-drug-resistant cancer cells.";
RL   Cell Death Dis. 2:e243.1-e243.8(2011).
//
RX   PubMed=25749379; DOI=10.18632/oncotarget.2889;
RA   Michaelis M., Rothweiler F., Loschmann N., Sharifi M., Ghafourian T.,
RA   Cinatl J. Jr.;
RT   "Enzastaurin inhibits ABCB1-mediated drug efflux independently of
RT   effects on protein kinase C signalling and the cellular p53 status.";
RL   Oncotarget 6:17605-17620(2015).
//